Arrowhead Pharmaceuticals, Inc. (ARWR) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Pasadena, CA, アメリカ. 現CEOは Christopher R. Anzalone.
ARWR を有する IPO日 1993-12-16, 609 名の正社員, に上場 NASDAQ Global Select, 時価総額 $9.34B.
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Pasadena, California, that develops RNA interference (RNAi) therapeutics for the treatment of intractable diseases. The company maintains a diverse clinical pipeline targeting liver diseases, metabolic disorders, cardiovascular conditions, respiratory diseases, and rare genetic disorders, with candidates in Phase 1 through Phase 3 clinical development. Key programs include ARO-AAT for alpha-1 antitrypsin deficiency, ARO-APOC3 for hypertriglyceridemia, ARO-HIF2 for renal cell carcinoma, and JNJ-3989 for chronic hepatitis B, developed under collaboration with Janssen Pharmaceuticals. Through strategic partnerships with leading pharmaceutical companies including Janssen and Takeda, Arrowhead leverages its RNAi platform technology to address genetically validated disease targets across multiple therapeutic areas.
